Immunome Stock Quote IMNM - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

14.39

Bid

14.39

Ask

14.44

Volume

737,149

13.8222 Day's Range 14.61

4.44 52 Week Range 30.958

Market Cap

609.755M

Previous Close

14.27

Open

14.20

Last Trade

14.42

Last Trade Time

Financial Volume

$ 10,538,526

VWAP

14.2963

Average Volume (3m)

806,876

Shares Outstanding

42,729,847

Dividend Yield

PE Ratio

-5.71

Earnings Per Share (EPS)

-2.5

Revenue

14.02M

Net Profit

-106.81M

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.immunome.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Immunome Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMNM. The last closing price for Immunome was $14.27. Over the last year, Immunome shares have traded in a share price range of $ 4.44 to $ 30.958.

Immunome currently has 42,729,847 shares outstanding. The market capitalization of Immunome is $609.75 million. Immunome has a price to earnings ratio (PE ratio) of -5.71.

Immunome Appoints Sandra M. Swain to Board of Directors

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D...

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for...

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into...

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase...

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and...

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

– Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing...

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-2.95	-17.0126874279	17.34	17.97	13.8222	1143465	15.4420421	CS
4	-11.14	-43.6349392871	25.53	25.75	13.8222	823843	18.7962856	CS
12	-2.51	-14.8520710059	16.9	30.958	13.8222	806876	22.04050191	CS
26	5.39	59.8888888889	9	30.958	6.93	521235	19.19869666	CS
52	9.0608	170.021766869	5.3292	30.958	4.44	335003	16.62905023	CS
156	-17.07	-54.2593769866	31.46	32.4476	2.09	190251	15.82421432	CS
260	-1.27	-8.1098339719	15.66	63.78	2.09	185317	17.75475372	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ISUNiSun Inc	$ 0.173 (84.04%)	19.85M
BRFHBarfresh Food Group Inc	$ 1.75 (69.90%)	41.45M
SGBXSafe and Green Holdings Corporation	$ 0.225 (56.14%)	132.51M
PCSAProcessa Pharmaceuticals Inc	$ 2.4137 (48.99%)	69.6M
BACKIMAC Holdings Inc	$ 5.065 (45.34%)	8.49M
EJHE Home Household Service Holdings Ltd	$ 0.767 (-73.64%)	12.36M
TVGNTevogen Bio Holdings Inc	$ 0.9057 (-39.62%)	328.69k
CSSEChicken Soup for the Soul Entertainment Inc	$ 0.265 (-37.69%)	16.75M
ATNIATN International Inc	$ 19.24 (-33.01%)	440.2k
BNAIBrand Engagement Network Inc	$ 2.59 (-30.56%)	234.29k
SQQQProShares UltraPro Short QQQ	$ 12.00 (1.61%)	159.11M
SGBXSafe and Green Holdings Corporation	$ 0.225 (56.14%)	132.51M
TSLATesla Inc	$ 170.18 (4.97%)	120.89M
ACONAclarion Inc	$ 0.383149 (33.04%)	115.37M
PEGYPineapple Energy Inc	$ 0.0517 (0.78%)	82.42M